Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Net Income (2016 - 2025)

Historic Net Income for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to -$25.1 million.

  • Editas Medicine's Net Income rose 5957.9% to -$25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.6 million, marking a year-over-year increase of 613.13%. This contributed to the annual value of -$237.1 million for FY2024, which is 5637.63% down from last year.
  • Editas Medicine's Net Income amounted to -$25.1 million in Q3 2025, which was up 5957.9% from -$51.5 million recorded in Q2 2025.
  • Over the past 5 years, Editas Medicine's Net Income peaked at -$18.9 million during Q4 2023, and registered a low of -$75.7 million during Q1 2025.
  • Its 5-year average for Net Income is -$50.2 million, with a median of -$51.5 million in 2025.
  • In the last 5 years, Editas Medicine's Net Income plummeted by 52431.9% in 2021 and then surged by 6894.66% in 2023.
  • Over the past 5 years, Editas Medicine's Net Income (Quarter) stood at -$41.4 million in 2021, then tumbled by 46.58% to -$60.7 million in 2022, then surged by 68.95% to -$18.9 million in 2023, then crashed by 140.68% to -$45.4 million in 2024, then surged by 44.67% to -$25.1 million in 2025.
  • Its last three reported values are -$25.1 million in Q3 2025, -$51.5 million for Q2 2025, and -$75.7 million during Q1 2025.